RxDoctor Payments DataLook up a doctor →

William Knubley, MD

Neurology · Fort Smith, ARNPI 1346269180

Payments from drug & device makers

$25,802in general payments, 2019–2025

Across 1,049 payments — averaging $24.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$8K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • AbbVie$2K
  • Novartis$2K
  • Amgen$1K
  • UCB, Inc.$920
  • plus $10K from 48 others

What the payments were for

  • Speaking & faculty fees$9,70038%
  • Food & beverage$15,98962%
  • Education$1130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,802 in reported general payments places this provider in the 75th percentile of 93 neurology providers in Arkansas.

See all neurology providers in Arkansas

Medicare billing

Part B allowed, 2024
$63,977
Medicare patients
303
Services billed
1,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine21$235,555
NuplazidPimavanserin Tartrate36$139,963
Kesimpta PenOfatumumab13$111,179
Nurtec OdtRimegepant Sulfate69$85,708
Aimovig AutoinjectorErenumab-Aooe86$81,596
BriviactBrivaracetam38$65,161
Emgality PenGalcanezumab-Gnlm86$61,731
UbrelvyUbrogepant52$56,192
Tetrabenazine13$52,906
FycompaPerampanel38$44,712
XcopriCenobamate24$35,536
RytaryCarbidopa/Levodopa34$28,492
BotoxOnabotulinumtoxina20$25,762
OngentysOpicapone21$22,282
Levetiracetam312$11,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$598$235,55521 claims
Acadia Pharmaceuticals IncNuplazid$632$139,96336 claims
PfizerNurtec Odt, Dilantin$328$89,58284 claims
AbbVieUbrelvy, Botox$1,970$81,95472 claims
UCB, Inc.Briviact$920$65,16138 claims
Eisai Inc.Fycompa$666$44,71238 claims
SK Life Science, Inc.Xcopri$796$35,53624 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$496$30,11758 claims
Neurocrine Biosciences, Inc.Ongentys$602$22,28221 claims
Upsher-smith Laboratories LLCTopiramate$214$1,375125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 93 neurology providers in Arkansas.

Other neurology in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →